PD-L1 Archives - BJBMS Blog

March 19, 2019

Latest posts

[ March 5, 2019 ] The scientists confirmed the necessity of early treatment of acute kidney injury (AKI) in reducing high-risk coronary diseases Author Summaries
[ February 20, 2019 ] The scientists highlighted importance of further research on electroencephalographic treatment Author Summaries
[ January 21, 2019 ] Researchers found EZH2 overexpression to be an indicator of poor prognosis in synovial sarcomas Author Summaries
[ January 9, 2019 ] Scientist report phenibut withdrawal to affect central nervous system receptors Author Summaries
[ November 12, 2018 ] BJBMS publishes November 2018 issue News

Positive PD-L1 (SP142 clone) IHC staining (2+, 85%) of a MSI-H colorectal tumor with concurrent BRAF V600E mutation; image taken at 20x magnification (Left image); Positive PD-1 (Cell Marque) IHC staining; image taken at 40x magnification (Right image).

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype

July 22, 2017 0

Le et al. recently reported (Science 10.1126/science.aan6733 (2017); (ClinicalTrials.gov number, NCT01876511) on the success of immune checkpoint blockade with anti-PD-1 antibodies in the patients whose cancers exhibited microsatellite instability-high (MSI-H) status. The study included 12 […]

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors

June 9, 2017 0

Targeted therapy based on the immune checkpoint inhibitors (Anti-PD1/PD-L1) has revolutionized cancer treatment and outcome of several solid and hematologic malignancies, including non-small cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, metastatic malignant melanoma, advanced/metastatic […]